Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Interferon Beta-1A · Avonex, Rebif

Recombinant protein · Immune activation, directed at Interferon beta receptor 1 (IFNAR1) · developed by Biogen

Approved FDA, May 1996

BIIB Developer

4 Registered trials

What is Interferon Beta-1A?

Interferon beta-1a is a recombinant cytokine that binds interferon beta receptors to activate immune responses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Avonex, Rebif, SNG-001, Interferon β-1a, Interferon beta type 1a, Rebif (IFNβ-1-a, Merck Europe B.V.)
Drug type: Recombinant protein
Targets: Interferon beta receptor 1 (IFNAR1)
Mechanism: Immune activation, directed at Interferon beta receptor 1 (IFNAR1)
Therapy area: Neurology
Developer: Biogen (BIIB)
FDA status: Approved as Avonex, Rebif (May 17, 1996), BLA103628 · FDA label
UNII: XRO4566Q4R

✅ FDA-approved uses

Relapsing forms of multiple sclerosis (Avonex)
Relapsing forms of multiple sclerosis (Rebif)

From the indications section of the FDA label (version of Nov 19, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03958877	Phase 3	Multiple Sclerosis, Relapsing-Remitting	Active not recruiting	BIIB
NCT02283853	Phase 3	Relapsing-Remitting Multiple Sclerosis	Completed	BIIB
NCT06053749	N/A	Multiple Sclerosis (MS)	Active not recruiting	BIIB
NCT05658497	N/A	Multiple Sclerosis	Recruiting	BIIB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple SclerosisMultiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingRelapsing-Remitting Multiple Sclerosis

Other drugs acting on IFNAR1

Anifrolumab FDA approved Interferon Alfa-2b FDA approved

More from Biogen

Dimethyl Fumarate FDA approved Diroximel Fumarate FDA approved Natalizumab FDA approved Nusinersen FDA approved Omaveloxolone FDA approved Tofersen FDA approved Zuranolone FDA approved BIIB115 Phase 1 BIIB122 Phase 3 BIIB144 Phase 1 BIIB147 Phase 1/2 Diranersen Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BIIB page.

Follow BIIB, the company behind Interferon Beta-1A

See BIIB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIIB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z